Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock's performance is highly tied to clinical trial results and the uptake of the company's new cancer drugs.
Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock's performance is highly tied to clinical trial results and the uptake of the company's new cancer drugs.
Share this Article
Recommended